Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance

Lantern Pharma Inc.

Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.
LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.
Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.
Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 18, 2024, Lantern Pharma Inc. (the "Company") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.